Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech Inc (USA) (O:ONCY)

Business Focus: Biotechnology & Medical Research

Mar 07, 2024 03:01 pm ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Mar 06, 2024 08:00 am ET
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.
Mar 05, 2024 08:30 am ET
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used...
Mar 05, 2024 06:00 am ET
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab
Mar 04, 2024 06:00 am ET
Feb 28, 2024 06:00 am ET
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
SAN DIEGO and CALGARY, AB, Feb. 28, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chief Executive Officer Dr. Matt Coffey will present a corporate overview at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference. The conference is taking place from February 29 - March 2, 2024, at the Ritz Carlton Hotel in New Orleans, LA. Additional details on the presentation can be found below.
Feb 15, 2024 08:00 am ET
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - February 15, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.
Feb 14, 2024 08:30 am ET
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diagnosed with anal cancer...
Feb 14, 2024 06:00 am ET
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion
Feb 14, 2024 06:00 am ET
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion
Jan 09, 2024 10:25 am ET
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of Americans aged 65 and older is projected to increase more than double over 95 million by the...
Jan 09, 2024 06:00 am ET
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").
Jan 09, 2024 06:00 am ET
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").
Jan 04, 2024 06:00 am ET
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024.
Jan 04, 2024 06:00 am ET
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024.
Dec 07, 2023 06:00 am ET
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor
Dec 07, 2023 06:00 am ET
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor
Nov 09, 2023 06:00 am ET
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response
Nov 09, 2023 06:00 am ET
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response
Nov 09, 2023 05:30 am ET
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
Updated plan follows PanCAN's strategic re-evaluation of the Precision PromiseSM Program
Nov 09, 2023 05:30 am ET
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
Updated plan follows PanCAN's strategic re-evaluation of the Precision PromiseSM Program
Nov 03, 2023 12:03 pm ET
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatmentAffirms pelareorep's ability to increase PD-L1 positive cells and T cell infiltration in the tumor microenvironmentData will support conduct of registrational program for pelareorepSAN DIEGO, CA and CALGARY, AB, Nov. 3, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of a poster that provides further positive translational data from the p
Nov 03, 2023 12:03 pm ET
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatmentAffirms pelareorep's ability to increase PD-L1 positive cells and T cell infiltration in the tumor microenvironmentData will support conduct of registrational program for pelareorepSAN DIEGO, CA and CALGARY, AB, Nov. 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of a poster that provides further positive translational data fro
Nov 03, 2023 07:00 am ET
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials
Nov 03, 2023 07:00 am ET
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials
Oct 23, 2023 07:05 am ET
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25%
Oct 23, 2023 07:05 am ET
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25%
Oct 23, 2023 07:00 am ET
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action
Oct 23, 2023 07:00 am ET
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action
Oct 20, 2023 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET
Oct 20, 2023 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET
Oct 16, 2023 07:00 am ET
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Preliminary updated PDAC data show 6-month overall survival rate of 82%
Oct 16, 2023 07:00 am ET
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Preliminary updated PDAC data show 6-month overall survival rate of 82%
Oct 13, 2023 09:00 am ET
Sep 28, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll?
NEW YORK, Sept. 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, NIR, BURCF, SEEL, and MLKN.
Sep 27, 2023 09:31 am ET
Thinking about buying stock in Arch Capital Group, Oncolytics Biotech, Baudax Bio, Femasys, or Traction Uranium?
NEW YORK, Sept. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACGL, ONCY, BXRX, FEMY, and TRCTF.
Sep 26, 2023 08:00 am ET
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies
Sep 26, 2023 07:00 am ET
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies
Sep 26, 2023 07:00 am ET
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies
Sep 19, 2023 07:00 am ET
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
SAN DIEGO and CALGARY, AB, Sept. 19, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its participation in an analyst-led fireside chat at the Cantor Global Healthcare Conference 2023 with Chief Executive Officer Dr. Matt Coffey. The conference is taking place September 26-28, 2023 at the InterContinental Barclay Hotel in New York, NY. Additional details on the fireside chat can be found below.
Sep 19, 2023 07:00 am ET
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
SAN DIEGO and CALGARY, AB, Sept. 19, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its participation in an analyst-led fireside chat at the Cantor Global Healthcare Conference 2023 with Chief Executive Officer Dr. Matt Coffey. The conference is taking place September 26-28, 2023 at the InterContinental Barclay Hotel in New York, NY. Additional details on the fireside chat can be found below.
Sep 07, 2023 09:22 am ET
Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
CALGARY, AB, Sept. 7, 2023 /CNW/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ: ONCY) (TSX: ONC) today announced that in connection with the previously announced underwritten public offering of US$15,000,750 (the "Offering") and the underwriting agreement dated August 1, 2023 (the "Underwriting Agreement"), Leede Jones Gable Inc. (the "Underwriter") has exercised their option (the "Over-Allotment Option"), in full, to purchase 1,000,050 units (the "Optioned Units") at US$2.25 for aggregate gross proceeds of US$2,250,112. The Company intends to use the proceeds from the
Sep 06, 2023 07:00 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and CALGARY, AB, Sept. 6, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023 at the Lotte New York Palace Hotel in New York, NY. Additional details on the fireside chat can be found below.
Aug 14, 2023 07:00 am ET
Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights
Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression
Aug 08, 2023 08:50 am ET
Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs
CALGARY, Alberta, Aug. 8, 2023 /CNW/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ: ONCY) (TSX: ONC) today announced the closing (the "Closing") of the previously announced underwritten public offering of US$15,000,750 (the "Offering"). An institutional investor was a significant participant in the Offering. The Company intends to use the proceeds from the Offering to continue the advancement of its pelareorep clinical programs in metastatic breast and pancreatic cancers, as well as general corporate and working capital purposes.
Aug 04, 2023 07:05 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference
SAN DIEGO and CALGARY, AB, Aug. 4, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at Canaccord Genuity's 43rd Annual Growth Conference, which is taking place August 7-10, 2023 at the InterContinental Boston in Boston, MA. Additional details on the fireside chat can be found below.
Aug 04, 2023 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET
Jul 31, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, INVO Bioscience, Troika Media Group, Allarity Therapeutics, or Barnes & Noble Education?
NEW YORK, July 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, INVO, TRKA, ALLR, and BNED.
Jul 31, 2023 06:55 am ET
Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units
Not for distribution to U.S. Newswire Services or Dissemination in the United States
Jul 28, 2023 09:31 am ET
Thinking about buying stock in Tupperware Brands, Oncolytics Biotech, Akebia Therapeutics, AMC Entertainment, or Enovix?
NEW YORK, July 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TUP, ONCY, AKBA, AMC, and ENVX.
Jul 26, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Rigetti Computing, Quantumscape, Vroom, or COMPASS Pathways?
NEW YORK, July 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, RGTI, QS, VRM, and CMPS.
Jul 24, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Archer Aviation, Plug Power, Virgin Galactic, or BigBear.a?
NEW YORK, July 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, ACHR, PLUG, SPCE, and BBAI.
Jul 21, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Tingo Group, Canoo, Akebia Therapeutics, or Bragg Gaming Group?
NEW YORK, July 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, TIO, GOEV, AKBA, and BRAG.
Jul 19, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Amarin Corporation, Biophytis, bluebird bio, or VERSES AI?
NEW YORK, July 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, AMRN, BPTS, BLUE, and VRSSF.
Jul 11, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Nikola Corp, Joby Aviation, Ideanomics, or Better Therapeutics?
NEW YORK, July 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, NKLA, JOBY, IDEX, and BTTX.
Jul 05, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Eos Energy Enterprises, Rivian Automotive, Carnival Corp, or Amneal Pharmaceuticals?
NEW YORK, July 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, EOSE, RIVN, CCL, and AMRX.
Jul 03, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Joby Aviation, VERSES AI, TMC the metals company, or VBI Vaccines?
NEW YORK, July 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, JOBY, VRSSF, TMC, and VBIV.
Jun 29, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, VERSES AI, Akebia Therapeutics, Sigilon Therapeutics, or BlackBerry?
NEW YORK, June 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, VRSSF, AKBA, SGTX, and BB.
Jun 27, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Nikola, American Equity Investment Life, Lordstown Motors, or Adicet Bio?
NEW YORK, June 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, NKLA, AEL, RIDE, and ACET.
Jun 22, 2023 07:00 am ET
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial
Jun 22, 2023 07:00 am ET
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial
Jun 05, 2023 07:00 am ET
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Ov
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy
Jun 05, 2023 07:00 am ET
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Ov
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy
Jun 01, 2023 10:45 am ET
Thinking about buying stock in OraSure Technologies, Quipt Home Medical, Talkspace, Frontline, or Oncolytics Biotech?
NEW YORK, June 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSUR, QIPT, TALK, FRO, and ONCY.
May 31, 2023 10:55 am ET
May 25, 2023 05:41 pm ET
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meetin
31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date
May 25, 2023 05:41 pm ET
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meetin
31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date
May 10, 2023 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, AB, May 10, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
May 10, 2023 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, AB, May 10, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
May 05, 2023 07:00 am ET
Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 05, 2023 07:00 am ET
Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 12, 2023 07:23 am ET
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
SAN DIEGO and CALGARY, AB, April 12, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023. Additional details on the panel presentation can be found below.
Apr 12, 2023 07:23 am ET
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023. Additional details on the panel presentation can be found below.
Apr 12, 2023 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET
Apr 12, 2023 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET
Mar 28, 2023 07:00 am ET
Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
SAN DIEGO and CALGARY, AB, March 28, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be found below.
Mar 28, 2023 07:00 am ET
Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
SAN DIEGO and CALGARY, AB, March 28, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be found below.
Mar 03, 2023 06:00 am ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients
Feb 21, 2023 06:00 am ET
Feb 21, 2023 06:00 am ET
Dec 08, 2022 07:45 am ET
Dec 08, 2022 07:45 am ET
Dec 01, 2022 08:25 am ET
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
PALM BEACH, Fla. , Dec. 1, 2022 /PRNewswire/ --  FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic cancer starts in the pancreas of the human body when abnormal cells in the pancreas grow and divide out of control and form a tumor. The presence of tumors prevents the normal functioning of the pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. Pancreatic cancer starts when the cells start growing abnormally and results in symptoms such as abdominal pain,
Nov 21, 2022 08:01 am ET
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
SAN DIEGO and CALGARY, AB, Nov. 21, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González Convention Center in San Antonio, Texas from December 6 – 10, 2022.
Nov 21, 2022 08:01 am ET
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
SAN DIEGO and CALGARY, AB, Nov. 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González Convention Center in San Antonio, Texas from December 6 – 10, 2022.
Nov 10, 2022 08:01 am ET
Nov 10, 2022 08:01 am ET
Nov 07, 2022 07:03 am ET
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials
Nov 07, 2022 07:03 am ET
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials
Nov 07, 2022 07:01 am ET
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4
Nov 07, 2022 07:01 am ET
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4
Oct 27, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Monday, November 7, 2022, at 8:30 a.m. ET
Oct 27, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Monday, November 7, 2022, at 8:30 a.m. ET
Oct 05, 2022 08:30 am ET
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
PALM BEACH, Fl, Oct. 5, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates remain high and essentially unchanged over the last two decades. Furthermore, even in the setting of adjuvant therapy, 5-year survival rates remain poor at only 25%, while for metastatic disease it is 1%. As a consequence, there is an ongoing need for the development of improved diagnostic techniques, trea
Sep 07, 2022 07:00 am ET
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries
Sep 07, 2022 07:00 am ET
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries
Aug 11, 2022 07:00 am ET
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer
Aug 11, 2022 07:00 am ET
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer
Jul 27, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET
Jul 27, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET
Jun 28, 2022 07:00 am ET
Jun 28, 2022 07:00 am ET
Jun 17, 2022 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc.
Jun 17, 2022 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc.
May 10, 2022 07:00 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, Calif. and CALGARY, AB, May 10, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference, which is taking place May 17-18, 2022 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.
May 10, 2022 07:00 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, Calif. and CALGARY, AB, May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference, which is taking place May 17-18, 2022 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.
May 05, 2022 04:01 pm ET
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial
May 05, 2022 04:01 pm ET
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial
May 04, 2022 07:00 am ET
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study
May 04, 2022 07:00 am ET
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study
May 02, 2022 07:00 am ET
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
SAN DIEGO, Calif. and CALGARY, AB, May 2, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 – Messe Berlin in Berlin, Germany from May 3-5, 2022.
May 02, 2022 07:00 am ET
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
SAN DIEGO, Calif. and CALGARY, AB, May 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 – Messe Berlin in Berlin, Germany from May 3-5, 2022.
Apr 28, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, May 5, 2022, at 5:00 p.m. ET
Apr 28, 2022 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, May 5, 2022, at 5:00 p.m. ET
Apr 21, 2022 07:00 am ET
Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference
SAN DIEGO, Calif. and CALGARY, AB, April 21, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference, which is taking place May 2-3, 2022 at the Metro Toronto Convention Centre, North Building in Toronto, Ontario. Additional details on the presentation can be found below.
Apr 21, 2022 07:00 am ET
Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference
SAN DIEGO, Calif. and CALGARY, AB, April 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference, which is taking place May 2-3, 2022 at the Metro Toronto Convention Centre, North Building in Toronto, Ontario. Additional details on the presentation can be found below.
Apr 14, 2022 08:33 am ET
Thinking about buying stock in Clarus Therapeutics, Oncolytics Biotech, Mersana Therapeutics, Veru, or Trevi Therapeutics?
NEW YORK, April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRXT, ONCY, MRSN, VERU, and TRVI.
Apr 12, 2022 07:00 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN DIEGO, Calif. and CALGARY, AB, April 12, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D., Ph.D., the Company's Chief Medical Officer, will be participating in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference. Additional details on the fireside chat are provided below.
Apr 12, 2022 07:00 am ET
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN DIEGO, Calif. and CALGARY, AB, April 12, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D., Ph.D., the Company's Chief Medical Officer, will be participating in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference. Additional details on the fireside chat are provided below.
Apr 08, 2022 01:05 pm ET
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting
- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication
Apr 08, 2022 01:05 pm ET
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting
- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication
Apr 08, 2022 01:03 pm ET
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting
- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy
Apr 08, 2022 01:03 pm ET
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting
- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy
Apr 06, 2022 07:00 am ET
Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress
SAN DIEGO, Calif. and CALGARY, AB, April 6, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
Apr 06, 2022 07:00 am ET
Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress
SAN DIEGO, Calif. and CALGARY, AB, April 6, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
Mar 24, 2022 08:30 am ET
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
PALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need for accurate and efficient treatment outcomes for the patient remains unparalleled. Furthermore, the strong trend of continuous R&D amongst key market players engaged in breast cancer therapeutics would lead to the launch of breakthrough therapeutics in the coming year
Mar 24, 2022 07:00 am ET
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date
Mar 24, 2022 07:00 am ET
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date
Mar 17, 2022 07:00 am ET
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
SAN DIEGO and CALGARY, AB, March 17, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," was published in collaboration with researchers at several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London. A link to the paper
Mar 17, 2022 07:00 am ET
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," was published in collaboration with researchers at several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London. A link to th
Mar 09, 2022 06:40 am ET
Mar 09, 2022 06:40 am ET
Mar 09, 2022 06:00 am ET
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking
Mar 09, 2022 06:00 am ET
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is
Mar 03, 2022 03:01 pm ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022
Mar 03, 2022 03:01 pm ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022
Feb 22, 2022 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
SAN DIEGO, Calif.  and CALGARY, AB, Feb. 22, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
Feb 22, 2022 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
SAN DIEGO, Calif.  and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
Jan 20, 2022 07:05 am ET
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).
Jan 20, 2022 07:05 am ET
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).
Jan 11, 2022 06:00 am ET
Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
Jan 11, 2022 06:00 am ET
Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
Jan 10, 2022 10:30 am ET
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
VANCOUVER, BC, Jan. 10, 2022 /PRNewswire/ -- USA News Group  -  Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as leukemia, lymphoma and myeloma. According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024, growing at a CAGR of 6.8%. Along the way, there have been several positive developments in the fight against blood cancers including more recent updates from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), AbbVie Inc. (NYSE:ABBV), Novartis AG (NYSE:NVS), Thermo Fisher Scientific Inc.
Dec 21, 2021 06:00 am ET
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
- Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations
Dec 21, 2021 06:00 am ET
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
- Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations
Nov 19, 2021 08:05 am ET
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC
Nov 19, 2021 08:05 am ET
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC
Nov 05, 2021 07:00 am ET
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker
Nov 05, 2021 07:00 am ET
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker
Nov 03, 2021 07:09 am ET
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer indications Trial builds on prior promising data from pancreatic and colorectal cancer trials SAN DIEGO and CALGARY, AB, Nov. 3, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the first patient has been dosed in the phase 1/2 GOBLET trial. The trial is being managed by AIO, a leading academic cooperative medical oncology group based i
Nov 03, 2021 07:09 am ET
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer indications Trial builds on prior promising data from pancreatic and colorectal cancer trials SAN DIEGO and CALGARY, AB, Nov. 3, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the first patient has been dosed in the phase 1/2 GOBLET trial. The trial is being managed by AIO, a leading academic cooperative medical oncology group based in Germa
Oct 19, 2021 09:44 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.
Oct 19, 2021 09:44 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.
Oct 14, 2021 07:54 am ET
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market
Oct 14, 2021 07:54 am ET
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market
Sep 20, 2021 08:00 am ET
Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris, France from September 14 – 17, 2021.
Sep 20, 2021 08:00 am ET
Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris, France from September 14 – 17, 2021.
Aug 06, 2021 07:00 am ET
Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer
Aug 06, 2021 07:00 am ET
Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer
Aug 06, 2021 06:30 am ET
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.
Aug 06, 2021 06:30 am ET
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.
Jul 22, 2021 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET
Jul 22, 2021 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET
Jun 30, 2021 07:00 am ET
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
SAN DIEGO and CALGARY, AB, June 30, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021. Presentation details are listed below.
Jun 30, 2021 07:00 am ET
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
SAN DIEGO and CALGARY, AB, June 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021. Presentation details are listed below.
May 20, 2021 07:00 am ET
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
May 13, 2021 07:00 am ET
May 10, 2021 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, AB, May 10, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting of Shareholders held on Friday, May 7, 2021. A total of 41.41% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
May 07, 2021 07:00 am ET
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
Apr 30, 2021 07:00 am ET
Oncolytics Biotech® Announces Annual General Meeting
Management will also provide its annual corporate update after the conclusion of the meeting
Apr 29, 2021 07:00 am ET
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
SAN DIEGO and CALGARY, AB, April 29, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021. Details on the abstract and a corresponding poster presentation are shown below.
Apr 12, 2021 07:02 am ET
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients
Apr 12, 2021 07:00 am ET
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
SAN DIEGO and CALGARY, AB, April 12, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The data are featured in two electronic poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Apr 08, 2021 07:00 am ET
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN DIEGO and CALGARY, Alberta, April 8, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Details on the panel discussion are provided below.
Apr 05, 2021 07:00 am ET
Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tum
SAN DIEGO and CALGARY, AB, April 5, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. The webinar will take place on Monday, April 12, 2021 at 2:00 pm ET.
Mar 10, 2021 03:32 pm ET
Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting
SAN DIEGO and CALGARY, AB, March 10, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies, in poster presentations during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Mar 05, 2021 06:32 am ET
Oncolytics Biotech® Establishes New At-The-Market Facility
SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /CNW/ ---- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to US$80 million. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics
Mar 05, 2021 06:30 am ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors
Feb 26, 2021 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 2021, at 8:30 am ET to discuss a corporate update and financial results for the fourth quarter and full year 2020.
Feb 26, 2021 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 2021, at 8:30 am ET to discuss a corporate update and financial results for the fourth quarter and full year 2020.
Feb 23, 2021 07:30 am ET
Thinking about buying stock in Vascular Biogenics, Oncolytics Biotech, Protalix Biotherapeutics, AMC Entertainment, or Applied DNA Sciences?
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VBLT, ONCY, PLX, AMC, and APDN.
Feb 23, 2021 06:00 am ET
Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors
Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model
Feb 23, 2021 06:00 am ET
Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors
Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model